Last $44.81 USD
Change Today -0.0399 / -0.09%
Volume 653.7K
PKI On Other Exchanges
Symbol
Exchange
New York
Berlin
As of 3:05 PM 09/2/14 All times are local (Market data is delayed by at least 15 minutes).

perkinelmer inc (PKI) Snapshot

Open
$44.95
Previous Close
$44.85
Day High
$45.36
Day Low
$44.76
52 Week High
07/3/14 - $48.26
52 Week Low
09/3/13 - $35.97
Market Cap
5.1B
Average Volume 10 Days
493.8K
EPS TTM
$1.89
Shares Outstanding
112.9M
EX-Date
10/15/14
P/E TM
23.7x
Dividend
$0.28
Dividend Yield
0.62%
Current Stock Chart for PERKINELMER INC (PKI)

perkinelmer inc (PKI) Related Businessweek News

No Related Businessweek News Found

perkinelmer inc (PKI) Details

PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, research, environmental, industrial, and laboratory services markets worldwide. The company operates through two segments, Human Health and Environmental Health. The Human Health segment develops diagnostics, tools, and applications to help detect diseases earlier, and to accelerates the discovery and development of critical new therapies. This segment provides early detection for genetic disorders from pre-conception to early childhood, as well as offers digital x-ray flat panel detectors and infectious disease testing for the diagnostics market; and a suite of solutions, such as reagents, liquid handling, and detection and imaging technologies that enable researchers to improve the drug discovery process. Its research portfolio includes instrumentation for automation and detection solutions, in vitro and in vivo imaging and analysis hardware and software, and a portfolio of consumable products, including drug discovery and research reagents. The Environmental Health segment provides services and solutions to facilitate the creation of safer food and consumer products, secure surroundings, and efficient energy resources. This segment offers analytical technologies, solutions, and services that enable its customers to understand the health aspects of environment, including air, water, soil, and food; analytical instrumentation for the industrial market that comprise the chemical, petrochemical, lubricant, electronics, semiconductor, and quality assurance industries; and laboratory services. The company markets its products and services under various brands directly through its own sales force. Its customers include pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. PerkinElmer, Inc. was founded in 1931 and is headquartered in Waltham, Massachusetts.

7,561 Employees
Last Reported Date: 08/5/14
Founded in 1931

perkinelmer inc (PKI) Top Compensated Officers

Chairman, Chief Executive Officer, President ...
Total Annual Compensation: $978.3K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $469.6K
Senior Vice President and President of Human ...
Total Annual Compensation: $341.0K
Chief Scientific Officer and Senior Vice Pres...
Total Annual Compensation: $430.7K
Senior Vice President, General Counsel and Se...
Total Annual Compensation: $394.6K
Compensation as of Fiscal Year 2013.

perkinelmer inc (PKI) Key Developments

PerkinElmer Inc. Reports Consolidated Earnings Results for the Second Quarter and Six Months Ended June 29, 2014; Provides Earnings Guidance for the Third Quarter and for the Full Year 2014

PerkinElmer Inc. reported consolidated earnings results for the second quarter and six months ended June 29, 2014. For the quarter, the company’s revenue was USD 556,170,000 against USD 540,673,000 a year ago. Operating income from continuing operations was USD 69,637,000 against USD 40,216,000 a year ago. Income from continuing operations before income taxes was USD 60,673,000 against USD 27,351,000 a year ago. Income from continuing operations was USD 52,003,000 or USD 0.46 per diluted share against USD 27,274,000 or USD 0.24 per diluted share a year ago. Net income was USD 50,490,000 or USD 0.44 per diluted share against USD 27,925,000 or USD 0.25 per diluted share a year ago. Adjusted Revenue was USD 556,596,000 against USD 544,472,000 a year ago. Adjusted operating income was USD 93,276,000 against USD 85,431,000 a year ago. Net cash provided by operating activities was USD 54,395,000 against USD 27,862,000 a year ago. Capital expenditures were USD 8,427,000 against USD 11,023,000 a year ago. Adjusted EPS was USD 0.59 against USD USD 0.51 a year ago. Adjusted earnings per share were USD 0.59 in the second quarter of 2014, at the high end of its guidance range, a result of strong margin realization on incremental revenues. For the six months, the company’s revenue was USD 1,086,780,000 against USD 1,043,616,000 a year ago. Operating income from continuing operations was USD 121,399,000 against USD 76,910,000 a year ago. Income from continuing operations before income taxes was USD 101,146,000 against USD 52,005,000 a year ago. Income from continuing operations was USD 86,954,000 or USD 0.76 per diluted share against USD 60,049,000 or USD 0.53 per diluted share a year ago. Net income was USD 84,714,000 or USD 0.74 per diluted share against USD 60,141,000 or USD 0.53 per diluted share a year ago. Adjusted Revenue was USD 1,088,658,000 against USD 1,049,347,000 a year ago. Adjusted operating income was USD 172,690,000 against USD 149,654,000 a year ago. Net cash provided by operating activities was USD 122,106,000 against USD 38,793,000 a year ago. Capital expenditures were USD 14,447,000 against USD 22,852,000 a year ago. Adjusted EPS was USD 1.05 against USD 0.86 a year ago. For the third quarter of 2014, the company expects adjusted revenues are expected to be in the range of USD 545 million to USD 555 million. Tax rate are expected to be consistent with the results in the second quarter, and cash flow is expected to remain robust in the second half as the company continues to better leverage its working capital. Adjusted earnings per share for the third quarter are expected to be in the range of USD 0.55 to USD 0.57. For the full year 2014, the company forecasts organic revenue to increase in the mid-single digit range relative to 2013. The company now forecasts GAAP earnings per share from continuing operations in the range of USD 1.89 to USD 1.93 and reiterates on a non-GAAP basis, which is expected to include the adjustments noted in the attached reconciliation, adjusted earnings per share in the range of USD 2.42 to USD 2.46.

PerkinElmer, Inc. Declares Quarterly Dividend, Payable on November 7, 2014

The board of directors of PerkinElmer Inc. declared a regular quarterly dividend of $0.07 per share of common stock on July 24, 2014. This dividend is payable on November 7, 2014, to all shareholders of record at the close of business on October 17, 2014.

PerkinElmer Launches Two New Automated Electrophoresis Systems

PerkinElmer Inc. has launched the new LabChip GX Touch and GXII Touch automated electrophoresis systems. The LabChip platform's key feature is automation of conventional gel electrophoresis, eliminating the need for manual sample preparation. The LabChip GX Touch and GXII Touch benefit customers by reducing hands-on time and simplifying data generation via a user friendly operator touch screen. The LabChip platform provides the data and throughput necessary to perform effective nucleic acid quantification and protein characterization. The LabChip GX system can enhance genomics research process by precisely quantifying nucleic acids. The GXII Touch system helps to accelerate the development of biotherapeutic drugs by automating the protein characterization process. The LabChip GXII Touch system's rapid reporting of multiple protein critical quality attributes can support customer needs throughout the product life cycle. The LabChip Touch platform's top differentiator is its ability to perform electrophoresis in microfluidic channels. The LabChip GX Touch system provides rapid, quantifiable data for pre and post-PCR sample analysis, which is critical for next-generation sequencing and genomics workflows. The LabChip GXII Touch system quantifies protein attributes from process development through quality control in biotherapeutics development and manufacturing.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PKI:US $44.81 USD -0.04

PKI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
IDEXX Laboratories Inc $124.08 USD +0.11
MEDNAX Inc $57.16 USD -0.09
QIAGEN NV €18.30 EUR -0.205
Sirona Dental Systems Inc $81.38 USD -0.13
Teleflex Inc $109.85 USD +0.37
View Industry Companies
 

Industry Analysis

PKI

Industry Average

Valuation PKI Industry Range
Price/Earnings 26.1x
Price/Sales 2.3x
Price/Book 2.5x
Price/Cash Flow 26.4x
TEV/Sales 1.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PERKINELMER INC, please visit www.perkinelmer.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.